108 related articles for article (PubMed ID: 19682512)
1. Clinical experience with anthracycline antibiotics-HPMA copolymer-human immunoglobulin conjugates.
Rihova B
Adv Drug Deliv Rev; 2009 Nov; 61(13):1149-58. PubMed ID: 19682512
[TBL] [Abstract][Full Text] [Related]
2. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.
Ríhová B; Strohalm J; Prausová J; Kubácková K; Jelínková M; Rozprimová L; Sírová M; Plocová D; Etrych T; Subr V; Mrkvan T; Kovár M; Ulbrich K
J Control Release; 2003 Aug; 91(1-2):1-16. PubMed ID: 12932633
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
4. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
5. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
6. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
7. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
Zhang L; Zhang R; Yang J; Wang J; Kopeček J
J Control Release; 2016 Aug; 235():306-318. PubMed ID: 27266365
[TBL] [Abstract][Full Text] [Related]
8. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
[TBL] [Abstract][Full Text] [Related]
10. Drug-HPMA-HuIg conjugates effective against human solid cancer.
Ríhová B; Strohalm J; Kubácková K; Jelínková M; Rozprimová L; Sírová M; Plocová D; Mrkvan T; Kovár M; Pokorná J; Etrych T; Ulbrich K
Adv Exp Med Biol; 2003; 519():125-43. PubMed ID: 12675212
[No Abstract] [Full Text] [Related]
11. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
Khasraw M; Bell R; Dang C
Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
[TBL] [Abstract][Full Text] [Related]
13. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
14. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death.
Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B
Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
Ozkan A; Ayhan A; Fiskin K
Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
[TBL] [Abstract][Full Text] [Related]
16. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.
Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R
J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
[TBL] [Abstract][Full Text] [Related]
18. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
19. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
20. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
